Abstract 6073
Background
Thyroid carcinomas are fairly uncommon tumors. They include disease types that range from indolent behavior such as papillary carcinomas to the fulminant and lethal anaplastic disease. The aim of this study was to analyze the characteristics of patients diagnosed with thyroid carcinoma in the United States between 2000 till 2016.
Methods
This study was conducted using SEER*Stat version 8.3.5 to analyze clinical and pathological characteristics of thyroid carcinoma patients diagnosed in the period between 2000 and 2016 in the United States through exploiting the data obtained from SEER Regs Research Data Nov 2018. The data were statistically analyzed using SPSS version 20.
Results
A total of 172525 cases of thyroid carcinoma were diagnosed. The median age at diagnosis was 50 years. Females were the most common gender affected (n = 131059; 75.7%). The incidence rate of thyroid carcinoma was estimated to be 12 per 100,000 cases. Papillary adenocarcinoma, NOS was the most common histology (n = 84323; 48.7%), followed by follicular variant of papillary carcinoma (n = 46830, 27.1%). The disease was the only primary tumor in most of cases (n = 139831; 80.8%). The majority of patients had localized early disease at the time of diagnosis (Stage I = 89235; 51.5%), and surgery was performed in the vast majority of case (n = 164742; 95.2%). The median survival wasn’t reached, with observed survival, at 5 and 10 years, was 94.2% & 89.2% respectively and relative survival at 5 and 10 years was 98% & 97.4%, respectively.
Conclusions
Thyroid carcinoma is a disease of middle ages, mainly, with female predominance. Papillary thyroid carcinoma is the most common histology and most of patients tend to present at early stage. The survival is good with median survival wasn’t reached and relative 5- year and 10- year survival of 98% & 97.4%, respectively.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
2107 - Role of Individualized Intervention(s) on Quality of Life (QOL) and Adherence to Adjuvant Endocrine Therapy in Premenopausal Women with Early-Stage Breast Cancer (BC): MyChoice Study
Presenter: Shahid Ahmed
Session: Poster Display session 2
Resources:
Abstract
5812 - Correlation between the density of tumor-infiltrating lymphocytes, immune cell subsets in tumor stroma and response to systemic therapy in breast cancer
Presenter: Cvetka Grasic Kuhar
Session: Poster Display session 2
Resources:
Abstract
4734 - BRCA1/2 Testing in HER2- Advanced Breast Cancer (ABC): Results from the European Component of a Multi-Country Real World Study
Presenter: Michael Patrick Lux
Session: Poster Display session 2
Resources:
Abstract
1686 - In vitro and in vivo rescue of resistance to BET inhibitors by targeting PLK1 in triple negative breast cancer.
Presenter: Cristina Nieto-jiménez
Session: Poster Display session 2
Resources:
Abstract
5020 - Neoadjuvant endocrine therapy in combination with melatonin and metformin in locally advanced breast cancer
Presenter: Tatiana Semiglazova
Session: Poster Display session 2
Resources:
Abstract
5082 - Melatonin and metformin in neoadjuvant chemotherapy in locally advanced breast cancer
Presenter: Tatiana Semiglazova
Session: Poster Display session 2
Resources:
Abstract
2642 - Patient-tailored tamoxifen dosing based on an increased quantitative understanding of its complex pharmacokinetics: A novel integrative modelling approach
Presenter: Anna Mueller-Schoell
Session: Poster Display session 2
Resources:
Abstract
2461 - Lack of benefit of neoadjuvant pertuzumab in high risk HER2 positive breast cancer. A retrospective case-control study of 355 cases with biomarker analysis.
Presenter: Manuela Tiako Meyo
Session: Poster Display session 2
Resources:
Abstract
4776 - Targeting CDCA3 to improve chemotherapy response in triple-negative breast cancer patients
Presenter: Kenneth O'Byrne
Session: Poster Display session 2
Resources:
Abstract
1674 - Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer
Presenter: María Del Mar Noblejas López
Session: Poster Display session 2
Resources:
Abstract